The enhancing effects of the light chain on heavy chain secretion in split delivery of factor VIII gene

Molecular Therapy

Volumn 15, Issue 10, 2007, Pages 1856-1862

  Chen, Lingxia ^a,g   Zhu, Fuxiang ^b   Li, Juan ^c   Lu, Hui ^a   Jiang, Haiyan ^d   Sarkar, Rita ^a   Arruda, Valder R ^a   Wang, Jinhui ^a   Zhao, Jennifer ^a   Pierce, Glenn F ^d   Ding, Qiulan ^e   Wang, Xuefeng ^e   Wang, Hongli ^e   Pipe, Steven W ^f   Liu, Xiang Qin ^b   Xiao, Xiao ^c   Camire, Rodney M ^a   Xiao, Weidong ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b DALHOUSIE UNIVERSITY   (Canada)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d BAYER CORPORATION   (United States)

^e SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^g PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BLOOD CLOTTING FACTOR 8; HYBRID PROTEIN; INTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE MUTATION; GENE TARGETING; GENE THERAPY; GLYCOSYLATION; HEAVY CHAIN; HEMOPHILIA A; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIGHT CHAIN; NONHUMAN; PLASMID; PROTEIN SECRETION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; BLOTTING, WESTERN; CELL LINE; FACTOR VIII; HUMANS; MICE; MICE, KNOCKOUT; PLASMIDS; PROTEIN PROCESSING, POST-TRANSLATIONAL;

ADENO-ASSOCIATED VIRUS; MUS;

EID: 34548796475     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300268     Document Type: Article

References (35)

1. Mann, KG(1999). Biochemistry and physiology of blood coagulation. Thromb Haemost 82: 165-174.
2. Kaufman, RJ (1999). Advances toward gene therapy for hemophilia at the millennium. Hum Gene Ther 10, 2091-2107.
3. Pipe, SW (2004). Coagulation factors with improved properties for hemophilia gene therapy. Semin Thromb Hemost 30: 227-237.
4. Couto, LB (2004). Preclinical gene therapy studies for hemophilia using adeno-associated virus (AAV) vectors. Semin Thromb Hemost 30 161-171.
5. Kay, MA and High, K (1999). Gene therapy for the hemophilias [comment]. Proc Natl Acad Sd USA 96: 9973-9975.
6. High, KA (2004). Clinical gene transfer studies for hemophilia B. Semin Thromb Hemost 30: 257-267.
7. Jiang, H, Lillicrap, D, Patarroyo-White, S, Liu, T, Qian, X, Scallan, CD et al. (2006). Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. Blood 108: 107-115.
8. Sarkar, R, Xiao, W and Kazazian, HH Jr. (2003). A single adeno-associated virus (AAV)-murine factor VIII vector partially corrects the hemophilia A phenotype. J Thromb Haemost 1: 220-226.
9. Scallan, CD, Liu, T, Parker, AE, Patarrovo-White, SL, Chen, H, Jiang, H et al. (2003). Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII. Blood 102: 3919-3926.
10. Burton, M, Nakai, H, Colosi, P, Cunningham, J, Mitchell, R and Couto, L (1999). Coexpression of factor VIII heavy and light chain adeno-associated viral vectors produces biologically active protein. Proc Natl Acad Sci USA 96: 12725-12730.
11. Mah, C, Sarkar, R, Zolotukhin, I, Schleissing, M, Xiao, X, Kazazian, HH et al. (2003). Dual vectors expressing murine factor VIII result in sustained correction of hemophilia A mice. Hum Gene Ther 14 143-152.
12. Kaufman, RJ (1989). Genetic engineering of factor VIII. Nature 342: 207-208.
13. Kaufman, RJ, Pipe, SW, Tagliavacca, L, Swaroop, M and Moussalli, M (1997). Biosynthesis, assembly and secretion of coagulation factor VIII. Blood Coagul Fibrinolysis 8 (suppl. 2): S3-S14.
14. Miao, HZ, Sirachainan, N, Palmer, L, Kucab, P, Cunningham, MA, Kaufman, RJ et al. (2004). Bioengineering of coagulation factor VIII for improved secretion. Blood 103: 3412-3419.
15. Cunningham, MA, Pipe, SW, Zhang, B, Hauri, HP, Ginsburg, D and Kaufman, RJ (2003). LMAN1 is a molecular chaperone for the secretion of coagulation factor VIII. J Thromb Haemost 1: 2360-2367.
16. Domer, AJ, Wasley, LC and Kaufman, RJ (1989). Increased synthesis of secreted proteins induces expression of glucose-regulated proteins in butyrate-treated Chinese hamster ovary cells. J Biol Chem 264 20602-20607.
17. Kaufman, RJ and Pipe, SW (1998). Can we improve on nature? "Super molecules" of factor VIII. Haemophilia 4: 370-379.
18. Toole, JJ, Pittman, DD, Orr, EC, Murtha, P, Wasley, LC and Kaulman, RJ (1986). A large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity, Proc Natl Acad Sci USA 83: 5939-5942.
19. Pittman, DD, Tomkinson, KN and Kaufman, RJ (1994). Post-translational requirements for functional factor V and factor VIII secretion in mammalian cells. J Biol Chem 269: 17329-17337.
20. Perler, FB (2004). The ins and outs of gene expression control. Nat Biotechnol 22: 824-826.
21. Wu, H, Hu, Z and Liu, XQ (1998). Protein trans-splicing by a spilt intein encoded in a split DnaE gene of Synechocystis sp. PCC6803. Proc Natl Acad Sci USA 95: 9226-9231.
22. Liu, XQ and Hu, Z (1997). A DnaB intein in Rhodothermus marinus: Indication of recent intein homing across remotely related organisms. Proc Natl Acad Sci USA 94: 7851-7856.
23. Wu, H, Xu, MQ and Liu, XQ (1998). Protein trans-splicing and functional mini-inteins of a cyanobacterial dnaB intein. Biochim Biophys Acta 1387:422-432.
24. Thompson, AR (2003). Structure and function of the factor VIII gene and protein. Semin Thromb Hemost 29:11-22.
25. Zhang, K, Shen, X, Wu, J, Sakaki, K, Saunders, T, Rutkowski, DT et al. (2006). Endoplasmic reticulum stress activates cleavage of CREBH to incluce a systemic inflammatory response. Cell 124: 587-599.
26. Brinkhous, K, Sandberg, H, Widlund, L, Read, M, Nichols, T, Sigman, J et al. (2002). Preclinical pharmacology of albumin-free B-domain deleted recombinant factor VIII. Semin Thromb Hemost 28: 269-272.
27. Pipe, SW (2005). The promise and challenges of bioengineered recombinant clotting factors. J Thromb Haemost 3: 1692-1701.
28. Pipe, SW and Kaufman, RJ (1996). Factor VIII C2 domain missense mutations exhibit defective trafficking of biologically functional proteins. J Biol Chem 271:25671-25676.
29. Kemball-Cook, G, Tuddenham, EG and Wacey, AJ (1998). The factor VIII Structure and Mutation Resource Site: HAMSTeRS version 4. Nucliec Acids Res 26: 216-219.
30. Giannelli, F, Green, PM, Sommer, SS, Poon, M, Ludwiq, M, Schwaab, R et al. (1998). Haemophilia B: Database of point mutations and short additions and delletions - eighth edition. Nucleic Acids Res 26 265-268.
31. Wang, Z, Ma, HI, Li, J, Sun, L, Zhang, J and Xiao, X (2003). Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther 10: 2105-2111.
32. Xiao, X, Li, J and Samulski, RJ (1996). Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 70: 8098-8108.
33. Sarkar, R, Tetreault, R, Gao, G, Wang, L, Bell, P, Chandler, R et al. (2004). Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype. Blood 103: 1253-1260.
34. Song, YK, Liu, F, Zhang, G and Liu, D (2002). Hydrodynamics-based transfection: Simple and efficient method for introducing and expressing transgenes in animals by intravenous injection of DNA. Methods Enzymol 346:92-105.
35. Liu, F, Song, Y and Liu, D (1999). Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 6 1258-1266.